Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s Puxitatug Samrotecan?

Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Metastatic Bile Duct Cancer.

Sep 19, 2023 - 20:00
Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Metastatic Bile Duct Cancer.
Read the original article

Tags:

Previous Article

Pharmanovia announces acquisition of Sanofi’s CNS brands

Next Article

Risk adjusted net present value: What is the current valuation of Merck’s MK-0616?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sarepta’s disappointing data put the FDA in a difficult spot

Sarepta’s disappointing data put the FDA in a difficult...

Nov 1, 2023

FDA warns some Philips respirators may not deliver the right treatment

FDA warns some Philips respirators may not deliver the ...

Apr 9, 2023

CMN-005 by CoImmune for B-Cell Non-Hodgkin Lymphoma: Li...

Sep 10, 2024